Alejandro D. Ricart

5.2k total citations · 2 hit papers
57 papers, 4.0k citations indexed

About

Alejandro D. Ricart is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Alejandro D. Ricart has authored 57 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 17 papers in Pathology and Forensic Medicine and 16 papers in Molecular Biology. Recurrent topics in Alejandro D. Ricart's work include Lymphoma Diagnosis and Treatment (15 papers), Colorectal Cancer Treatments and Studies (12 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Alejandro D. Ricart is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Colorectal Cancer Treatments and Studies (12 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Alejandro D. Ricart collaborates with scholars based in United States, France and Italy. Alejandro D. Ricart's co-authors include Arun Balakumaran, Margaret A. Shipp, Craig H. Moskowitz, Pier Luigi Zinzani, Philippe Armand, Anthony W. Tolcher, Sinil Kim, Jean‐Marie Michot, Vincent Ribrag and Ellen Snyder and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Alejandro D. Ricart

56 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

2017 694 citations Robert Chen, Pier Luigi Zinzani et al. Journal of Clinical Oncology profile →
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

2016 477 citations Philippe Armand, Margaret A. Shipp et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alejandro D. Ricart United States	24	2.5k	1.4k	1.0k	780	762	57	4.0k
Roman K. Thomas Germany	37	3.1k 1.2×	2.6k 1.9×	751 0.7×	707 0.9×	2.0k 2.7×	95	5.7k
Matthew H. Taylor United States	36	3.5k 1.4×	1.4k 0.9×	558 0.5×	1.1k 1.5×	1.6k 2.1×	173	6.4k
Drew Rasco United States	33	2.4k 1.0×	1.7k 1.2×	422 0.4×	870 1.1×	980 1.3×	192	4.1k
Núria Viñolas Spain	33	1.5k 0.6×	1.6k 1.1×	634 0.6×	601 0.8×	1.5k 1.9×	123	4.3k
Andréa Varga France	33	3.0k 1.2×	1.2k 0.8×	527 0.5×	816 1.0×	1.2k 1.6×	107	4.6k
Socorro Marıá Rodríguez-Pinilla Spain	30	2.0k 0.8×	1.6k 1.1×	1.1k 1.1×	421 0.5×	341 0.4×	97	3.8k
David Hogg Canada	40	4.0k 1.6×	3.3k 2.3×	540 0.5×	1.2k 1.5×	1.1k 1.4×	124	6.3k
Anastasios Stathis Switzerland	31	2.0k 0.8×	2.6k 1.9×	1.4k 1.4×	355 0.5×	571 0.7×	198	4.9k
Silvio Veronese Italy	31	3.6k 1.5×	1.6k 1.1×	1.5k 1.4×	307 0.4×	2.0k 2.6×	91	5.4k
David S. Rickman United States	34	1.4k 0.6×	2.8k 2.0×	855 0.8×	496 0.6×	1.6k 2.1×	63	5.6k

Countries citing papers authored by Alejandro D. Ricart

Since Specialization

Citations

This map shows the geographic impact of Alejandro D. Ricart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandro D. Ricart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandro D. Ricart more than expected).

Fields of papers citing papers by Alejandro D. Ricart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alejandro D. Ricart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandro D. Ricart. The network helps show where Alejandro D. Ricart may publish in the future.

Co-authorship network of co-authors of Alejandro D. Ricart

This figure shows the co-authorship network connecting the top 25 collaborators of Alejandro D. Ricart. A scholar is included among the top collaborators of Alejandro D. Ricart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alejandro D. Ricart. Alejandro D. Ricart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheah, Chan Y., Wojciech Jurczak, Masa Lasica, et al.. (2021). TG-1701 A selective bruton tyrosine kinase (btk) inhibitor, as monotherapy and in combination with ublituximab and umbralisib (u2) in chronic lymphocytic leukemia (cll) and lymphoma. HemaSphere. 286–286. 1 indexed citations

Chen, Robert, Pier Luigi Zinzani, Michelle A. Fanale, et al.. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. Journal of Clinical Oncology. 35(19). 2125–2132. 694 indexed citations breakdown →

Fanale, Michelle A., Justin Kline, Gilles Salles, et al.. (2016). Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (cHL): randomized phase 3 KEYNOTE-204 study. Annals of Oncology. 27. vi327–vi327. 1 indexed citations

Bruce, Justine Y., Patricia LoRusso, Priscila Gonçalves, et al.. (2016). A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 77(3). 527–538. 3 indexed citations

Ricart, Alejandro D.. (2014). New FDA breakthrough-drug category--implications for patients.. New England Journal of Medicine. 371(1). 89. 6 indexed citations

Raez, Luis E., Kyriakos P. Papadopoulos, Alejandro D. Ricart, et al.. (2012). A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 71(2). 523–530. 411 indexed citations

Boasberg, Peter D., Charles H. Redfern, Gregory A. Daniels, et al.. (2011). Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemotherapy and Pharmacology. 68(2). 547–552. 56 indexed citations

Mita, Alain C., K. Papadopoulos, Maja J.A. de Jonge, et al.. (2011). Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. British Journal of Cancer. 105(7). 938–944. 36 indexed citations

Ricart, Alejandro D., Edward Ashton, Matthew M. Cooney, et al.. (2011). A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 68(4). 959–970. 27 indexed citations

10.

Spano, Jean‐Philippe, Malcolm J. Moore, Yazdi K. Pithavala, et al.. (2011). Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Investigational New Drugs. 30(4). 1531–1539. 15 indexed citations

11.

Wasan, Harpreet, Gregory M. Springett, Catherine Chodkiewicz, et al.. (2009). CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. British Journal of Cancer. 101(7). 1162–1167. 35 indexed citations

12.

Mita, Monica, Alain C. Mita, Quincy S. Chu, et al.. (2008). Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies. Journal of Clinical Oncology. 26(3). 361–367. 227 indexed citations

13.

Spano, Jean‐Philippe, Catherine Chodkiewicz, Joan Maurel, et al.. (2008). Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. The Lancet. 371(9630). 2101–2108. 204 indexed citations

14.

Ricart, Alejandro D., Anthony W. Tolcher, Glenn Liu, et al.. (2008). Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study. Clinical Cancer Research. 14(23). 7924–7929. 130 indexed citations

15.

Sankhala, Kamalesh K., Alain C. Mita, Alejandro D. Ricart, et al.. (2007). A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors. Molecular Cancer Therapeutics. 6. 2 indexed citations

16.

Papadopoulos, Kyriakos P., Alain C. Mita, Alejandro D. Ricart, et al.. (2007). Pharmacokinetic findings from the phase I study of Quarfloxin (CX-3543): a protein-rDNA quadruplex inhibitor, in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 6. 10 indexed citations

17.

LoRusso, Patricia, Smitha Krishnamurthi, Lisle Nabell, et al.. (2007). Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer. Molecular Cancer Therapeutics. 6. 13 indexed citations

18.

Ricart, Alejandro D. & Anthony W. Tolcher. (2007). Technology Insight: cytotoxic drug immunoconjugates for cancer therapy. Nature Clinical Practice Oncology. 4(4). 245–255. 67 indexed citations

19.

Raez, Luis E., Virginia K. Langmuir, Alejandro D. Ricart, et al.. (2006). Phase I trial of glycolitic inhibition with 2-deoxyglucose and docetaxel for patients with solid tumors. Cancer Research. 66. 121–122. 4 indexed citations

20.

Ricart, Alejandro D., Anthony W. Tolcher, Quincy S. Chu, et al.. (2006). Phase I study of BMS-247550, an epothilone B analog, administered weekly for 3 weeks followed by a one-week break in patients (pts) with advanced malignancies. Cancer Research. 66. 685–685. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact